Drug intelligence / Profile preview

IMC-003

Development stage: Phase 2
Lead developer: ImmuneOnco
Administration: Injection

Overview

IMC-003, also known as IMM72, is a new generation activin receptor type IIA-Fc (ActRIIA-Fc) fusion protein. Developed by ImmuneOnco Biopharmaceuticals (Shanghai) Inc., it is designed to inhibit Activin Receptor Type IIA. The drug is currently undergoing Phase I clinical trials to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy postmenopausal women. Additionally, it is in development for the treatment of pulmonary arterial hypertension (PAH).

Other names: ICTWIST

Targets

GDF8 (Myostatin)ACVR2A (Activin receptor type 2A)

Beyond the preview

Go deeper on IMC-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMC-003.